Navigation Links
Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
Date:7/30/2009

QUEBEC CITY, July 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has achieved additional positive results with its vaccine candidate for the Influenza A (H1N1) virus, also known as Swine flu. Results showed that a single dose of 5 micrograms induced a positive immune response against a new emerging strain of this virus in 100% of vaccinated animals.

Medicago's H1N1 VLP vaccine was formulated to protect against the influenza A/California/04/09 virus ("California/04"), which was one of the original viral strains selected by the WHO for vaccine manufacturers. The Company previously reported data from an initial study in mice where its novel vaccine achieved a positive immune response in 100% of the animals vaccinated against the California/04 virus. In a continuation of this study, Medicago tested the immune response of its H1N1 vaccine against the California/07 virus, a more current and mutated strain and showed positive immune response after a single dose of 5 micrograms. The challenge of current pandemic influenza vaccines is they have to match the circulating strain in order to be effective.

"We have already demonstrated the speed of our technology by producing an H1N1 vaccine candidate and initiating animal testing while other vaccine manufacturers were still waiting for a seed strain from the WHO. These additional data expand upon the results we announced in June and support our belief that our influenza vaccines are also capable of providing protection against different circulating viral strains," said Andy Sheldon, President and CEO of Medicago. "Unlike current vaccine manufacturers that have experienced difficulties producing a pandemic candidate for H1N1, our H1N1 vaccine candidate was well expressed in our plant-based system and has produced good yields."

Vaccine makers currently developing vaccine candidates for the pandemic swine flu using egg-based and cell culture technologies have advised the WHO that the influenza seed strain used to produce their new vaccine is not growing well and therefore giving poor antigen yields. The yield is approximately 25-50% of that vaccine makers typically get for seasonal flu vaccine production. The WHO recently made a new set of seed strains using new viral isolates, such as the California/07, in hopes of increasing the vaccine yield. Medicago's vaccine is produced using its VLP technology that does not require a virus and therefore does not rely on the ability of a viral strain to grow.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
2. Vical Presentation at Military Pandemic Influenza Workshop
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. NASA technology helps predict and prevent future pandemic outbreaks
5. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
6. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
7. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
8. H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria
9. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
10. CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans
11. Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... March 22, 2017 Oramed Pharmaceuticals Inc. ... www.oramed.com ), a clinical-stage pharmaceutical ... delivery systems, announced today that Dr. Miriam ... a presentation titled, "Oral Insulin for Diabetes Treatment: ... Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... March 22, 2017   Boston Biomedical , an ... designed to target cancer stemness pathways, today announced its ... as Chief Executive Officer, effective April 24, 2017. ... J. Li , M.D., FACP, who has led Boston ... Under his leadership, Boston Biomedical has grown from a ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Benchworks ... Science Chief Executive Officer Forum on March 23-24 in San Diego. The event ... device and diagnostic industries. , Benchworks Vice President Christian Meyer will also participate ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):